Clinical trial
Gefitinib in Treating Patients With Recurrent or Metastatic Esophageal or…
NCT00268346 · Case Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00268346 |
|---|---|
| Title | Gefitinib in Treating Patients With Recurrent or Metastatic Esophageal or Gastroesophageal Junction Cancer |
| Official title | A Phase II Trial of ZD1839 (IRESSA®) for Patients With Recurrent or Metastatic Cancer of the Esophagus or Gastroesophageal Junction |
| Lead sponsor | Case Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Esophageal Cancer |
| Intervention type | Drug |
| Interventions | ZD1839 |
| Enrollment | 58 |
| Start date | Oct 1, 2005 |
| Primary completion | Jan 1, 2011 |
| Completion | Aug 1, 2011 |
| First posted | Dec 22, 2005 |
| Last update posted | Jan 5, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: